India, Oct. 21 -- Voyager Therapeutics Inc. (VYGR), a biotechnology company developing treatments for neurological diseases, said Wednesday Robin Swartz has been appointed president. Her appointment took effect on October 20, 2026.
Swartz, the company's chief business officer and chief operating officer, is expected to succeed Alfred W. Sandrock Jr. as CEO in the first quarter of 2027.
The transition is expected to follow receipt of initial acute safety data from a trial of VY1706, Voyager's investigational tau-silencing gene therapy in adults with early Alzheimer's disease. The company expects the initial safety data in the first quarter of 2027, depending on patient enrollment.
Sandrock is expected to remain CEO through that milestone ...